P1-091: Investigation of APP Pathophysiology in C. Elegans

Mary E. Wiese,Adam Antebi,Hui Zheng
DOI: https://doi.org/10.1016/j.jalz.2008.05.677
2008-01-01
Abstract:Mutations in APP leading to the development of Familial Alzheimer's Disease (FAD) has been well established, however, the normal functional role of this protein within the neuron has proven elusive. We are using the model organism Caenorhabditis elegans to investigate the pathophysiology of APP. This system is relevant to the mammalian system as both APP and key synaptic transmission pathways are highly conserved. C. elegans are particularly attractive for the study of APP because the amyloid precursor-like protein 1 (apl-1) is the only homolog of APP in the worm, while mammals contain two others, APLP1 and APLP2. The genetic redundancies from the APP homologs make analysis of APP function in mice challenging, however, in worms null mutation in the apl-1 gene leads to a lethal larval arrest, allowing direct assessment of the apl-1/APP structure and function by genetic rescue. In addition to physiological investigation, C. elegans also offer distinct advantages to study neuronal and aging pathways relevant to AD pathogenesis. To investigate the role of apl-1/APP in the regulation of cholinergic neurotransmission RNAi knockdown of apl-1 was performed followed by drug testing on the acetylcholine esterase inhibitor aldicarb. Classical epistasis experiments were performed to determine where apl-1 operates in synaptic transmission. In addition, we created transgenic worms expressing human APPC99 in neurons in order to generate a model with which to study the pathogenesis of Aβ. Consistent with an essential role for APP family of proteins in the regulation of cholinergic neurotransmission in the mouse neuromuscular junction, we show that RNAi knockdown of apl-1 leads to hypersensitivity to aldicarb. Through epistasis we have found that apl-1 operates after the action of the synaptic vesicle docking protein unc-18. In worms expressing APPC99, genetic crosses reveal that trafficking of this molecule is kinesin-dependent. Loss of apl-1/APP leads to excessive secretion of acetylcholine. apl-1/APP acts at the pre-synaptic compartment after the vesicle docking stage of synaptic vesicle exocytosis. Currently, we are performing structural/functional studies to map the domains required for apl-1/APP function as well as evaluating the processing of APPC99, Aβ pathology and effects of aging on pathology.
What problem does this paper attempt to address?